On February 20, 2025, HCW Biologics Inc. entered into an Equity Purchase Agreement allowing it to sell up to $20 million in shares to Square Gate Capital over 36 months, with a commitment fee of $150,000 in shares. The company will use proceeds from this agreement to support clinical development and research activities.